Can Fite Biopharma Stock Current Valuation
| CANF Stock | USD 1.60 0.09 5.96% |
Valuation analysis of Can Fite Biopharma helps investors to measure Can Fite's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Undervalued
Today
Please note that Can Fite's price fluctuation is risky at this time. Calculation of the real value of Can Fite Biopharma is based on 3 months time horizon. Increasing Can Fite's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Can stock is determined by what a typical buyer is willing to pay for full or partial control of Can Fite Biopharma. Since Can Fite is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Can Stock. However, Can Fite's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.6 | Real 4.65 | Hype 1.6 | Naive 1.65 |
The real value of Can Stock, also known as its intrinsic value, is the underlying worth of Can Fite Biopharma Company, which is reflected in its stock price. It is based on Can Fite's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Can Fite's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Can Fite Biopharma helps investors to forecast how Can stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Can Fite more accurately as focusing exclusively on Can Fite's fundamentals will not take into account other important factors: Can Fite Biopharma Company Current Valuation Analysis
Can Fite's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Can Fite Current Valuation | 4.81 M |
Most of Can Fite's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Can Fite Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Can Fite Biopharma has a Current Valuation of 4.81 M. This is 99.97% lower than that of the Biotechnology sector and 99.9% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.97% higher than that of the company.
Can Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Can Fite's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Can Fite could also be used in its relative valuation, which is a method of valuing Can Fite by comparing valuation metrics of similar companies.Can Fite is currently under evaluation in current valuation category among its peers.
Can Fundamentals
| Return On Equity | -1.58 | ||||
| Return On Asset | -0.57 | ||||
| Operating Margin | (12.96) % | ||||
| Current Valuation | 4.81 M | ||||
| Shares Outstanding | 6.1 M | ||||
| Shares Owned By Institutions | 1.49 % | ||||
| Number Of Shares Shorted | 255.92 K | ||||
| Price To Earning | (3.41) X | ||||
| Price To Book | 3.71 X | ||||
| Price To Sales | 14.62 X | ||||
| Revenue | 743 K | ||||
| Gross Profit | 667 K | ||||
| EBITDA | (8.18 M) | ||||
| Net Income | (7.63 M) | ||||
| Cash And Equivalents | 12.77 M | ||||
| Cash Per Share | 0.47 X | ||||
| Total Debt | 40 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 6.78 X | ||||
| Book Value Per Share | 0 X | ||||
| Cash Flow From Operations | (8.44 M) | ||||
| Short Ratio | 2.39 X | ||||
| Earnings Per Share | (2.60) X | ||||
| Target Price | 14.0 | ||||
| Beta | 0.26 | ||||
| Market Capitalization | 9.75 M | ||||
| Total Asset | 9.99 M | ||||
| Retained Earnings | (158.48 M) | ||||
| Working Capital | 7.89 M | ||||
| Current Asset | 39.51 M | ||||
| Current Liabilities | 5.77 M | ||||
| Net Asset | 9.99 M |
About Can Fite Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Can Fite Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Can Fite using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Can Fite Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Can Fite Biopharma is a strong investment it is important to analyze Can Fite's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Can Fite's future performance. For an informed investment choice regarding Can Stock, refer to the following important reports:Check out Can Fite Piotroski F Score and Can Fite Altman Z Score analysis. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Can Fite. If investors know Can will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Can Fite listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Can Fite Biopharma is measured differently than its book value, which is the value of Can that is recorded on the company's balance sheet. Investors also form their own opinion of Can Fite's value that differs from its market value or its book value, called intrinsic value, which is Can Fite's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Can Fite's market value can be influenced by many factors that don't directly affect Can Fite's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Can Fite's value and its price as these two are different measures arrived at by different means. Investors typically determine if Can Fite is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Can Fite's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.